NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$83.16
-2.75 (-3.20%)
Close of Nov 06, 2026 · end-of-day data
CRVL 8-K filings in 2023
Every material Form 8-K CorVel filed with the SEC in 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CorVel reported results for the three months ended September 30, 2023, with revenue of $196 million, up from $177 million a year earlier, and diluted earnings per share of $1.15, up from $0.83. For the six months, revenue was $386 million and diluted EPS was $2.29, compared with $354 million and $1.77 a year earlier. The filing gives no guidance for future periods.
Quarter revenue $196 million vs $177 million a year earlier; net income $19.9 million vs $14.7 million
Quarter diluted EPS $1.15 vs $0.83 in the prior-year quarter
Six-month revenue $386 million vs $354 million; six-month diluted EPS $2.29 vs $1.77
Press release cites CERIS payment integrity growth and new bookings; no forward guidance was given
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CorVel filing is on SEC EDGAR ↗. 8-K briefs of other companies →